Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



@@#116300@@

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le lundi 3 février 2020
Doi : 10.1016/j.jaad.2019.12.015
accepted : 6 December 2019
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
 

Hidemi Nakagawa, MD, PhD a, Osamu Nemoto, MD, PhD b, Atsuyuki Igarashi, MD, PhD c, Hidehisa Saeki, MD, PhD d, Hironobu Kaino, MS e, Takeshi Nagata, MS e,
a Jikei University School of Medicine, Tokyo, Japan 
b Kojinkai Sapporo Skin Clinic, Hokkaido, Japan 
c Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan 
d Department of Dermatology, Nippon Medical School, Tokyo, Japan 
e Pharmaceutical Division, Japan Tobacco Inc, Tokyo, Japan 

Reprint requests: Takeshi Nagata, MS, Pharmaceutical Division, Japan Tobacco Inc, Torii Nihonbashi Bldg 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo, 103-0023 Japan.Pharmaceutical DivisionJapan Tobacco IncTorii Nihonbashi Bldg 4-1, Nihonbashi-Honcho 3-chome, Chuo-kuTokyo103-0023Japan
Abstract
Background

Previous studies showed the potential effectiveness of delgocitinib ointment, a novel topical Janus kinase inhibitor, in atopic dermatitis (AD).

Objective

This study aimed to evaluate the efficacy and safety of delgocitinib 0.5% ointment.

Methods

In part 1, a 4-week double-blind period, Japanese patients aged 16 years or older with moderate or severe AD were randomly assigned in a 2:1 ratio to delgocitinib 0.5% ointment or vehicle ointment. Eligible patients entered part 2, a 24-week extension period, to receive delgocitinib 0.5% ointment.

Results

At the end of treatment in part 1, the least-squares mean percent changes from baseline in the modified Eczema Area and Severity Index score, the primary efficacy endpoint, were significantly greater in the delgocitinib group than in the vehicle group (-44.3% vs 1.7%, P  < .001). The improvement in modified Eczema Area and Severity Index score was maintained in part 2. Most adverse events were mild and unrelated to delgocitinib across the study periods.

Limitations

Only Japanese patients were included. The vehicle-controlled period lasted only 4 weeks. In part 2, topical corticosteroids were allowed for the treatment of worsening of AD.

Conclusion

Delgocitinib ointment was effective and well tolerated in Japanese adult patients with moderate to severe AD for up to 28 weeks.

The full text of this article is available in PDF format.

Key words : Atopic dermatitis, delgocitinib, eczema, inflammation, JAK inhibitor, Janus kinase, JTE-052, ointment, pruritus, QOL, skin barrier, topical therapy

Abbreviation used : AD, AE, BSA, EASI, EOT, IGA, IL, JAK, mEASI, mEASI-50, mEASI-75, NRS, STAT, Th



 Funding sources: Supported by Japan Tobacco Inc. Japan Tobacco Inc. contributed to the study design, data collection, analysis, and interpretation of the data and provided medical writing assistance for the manuscript. All authors made the decision to submit the manuscript for publication.
 Disclosure: Dr Nakagawa received consulting fees and/or speaker honoraria from AbbVie, Eisai, Eli Lilly Japan, Janssen, Japan Tobacco Inc, Kyowa Hakko Kirin, LEO Pharma, Maruho, Novartis, Tanabe Mitsubishi, Torii Pharmaceutical, and UCB Japan. Dr Nemoto received advisory board honoraria and/or speaker honoraria from Japan Tobacco Inc., Kyowa Hakko Kirin, LEO Pharma, and Maruho. Dr Igarashi received advisory board honoraria, consulting fees, or speaker honoraria from AbbVie, Eli Lilly Japan, Japan Tobacco Inc, Maruho, Novartis, Sanofi, and Torii Pharmaceutical and received research grants from AbbVie, Eli Lilly Japan, Japan Tobacco Inc, Novartis, and Sanofi. Dr Saeki received advisory board honoraria and/or speaker honoraria from Japan Tobacco Inc, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Maruho, Taiho Pharma, Tanabe Mitsubishi, and Torii Pharmaceutical and received research grants from AbbVie, Japan Tobacco Inc, LEO Pharma, Maruho, Otsuka Pharmaceutical, and Sanofi. Mr Kaino and Mr Nagata are employees of Japan Tobacco Inc.
 The results of part 1 of the study were presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC, on March 1-2, 2019.
 IRB approval status: Study-related documents, including the study protocol and informed consent forms, were reviewed by the Sugiura Clinic IRB on April 4, 2017, Atago Dermatology Clinic IRB on April 28, 2017, Osaka University Hospital IRB on March 28, 2017, Tokyo Teishin Hospital IRB on April 19, 2017, and Jichi Medical University Hospital IRB on April 28, 2017. The conduct of the study was approved for all the study sites.



© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline